SCHEMBL10081090

SCHEMBL10081090

Cc1cncc(-c2ccc3nc(Nc4cnn(C)c4)sc3c2)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 11/20 0.58
PIK3CA P42336 7/20 0.47
PIK3CD O00329 3/20 0.47
PIK3CB P42338 2/20 0.47
PI4KA P42356 2/20 0.47
PI4KB Q9UBF8 2/20 0.47
PCSK9 Q8NBP7 1/20 0.42
ITK Q08881 1/20 0.41
ABL1 P00519 3/20 0.40
KIT P10721 1/20 0.39
PDGFRA P16234 1/20 0.39
PIP5K1C O60331 1/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 2/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10081095 0.86 PIK3CG (0.55) PIK3CGPIK3CAPIK3CDPIK3CBPI4KA
SCHEMBL10084741 0.85 PIK3CD (0.56) PIK3CGPIK3CAPIK3CDPIK3CBPI4KA
SCHEMBL10081097 0.84 PIK3CG (0.51) PIK3CGPIK3CAPIK3CDPIK3CBPI4KA
SCHEMBL10081089 0.83 PIK3CG (0.64) PIK3CGPIK3CAPIK3CDPIK3CBPI4KA
SCHEMBL10081159 0.83 PIK3CG (0.64) PIK3CGPIK3CAABL1MEN1NPC1
SCHEMBL12342693 0.83 PIK3CG (0.49) PIK3CGPIK3CAPIK3CDPIK3CBPI4KA
SCHEMBL10081098 0.82 PIK3CG (0.58) PIK3CGPIK3CAPIK3CDABL1NPC1
SCHEMBL10081096 0.81 PIK3CG (0.57) PIK3CGPIK3CAPIK3CD
SCHEMBL10081094 0.80 PIK3CG (0.58) PIK3CGPIK3CAPIK3CDPIK3CBPI4KA
SCHEMBL10081088 0.80 PIK3CG (0.60) PIK3CGPIK3CAPIK3CDPI4KAPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268999-B2 Tri-cyclic pyrazolopyridine kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-18 US disclosed
US-20120053187-A1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053187-A1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS PIK3CA, PIK3CD, PIK3CG PIK3CG 3/4885PIK3CA 1/4885PIK3CD 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.